|
|
1
|
Sheep's heart
|
|
2
|
Microvasculature of sheep's heart
|
|
3
|
Microvasculature of sheep's heart-higher magnification
|
|
4
|
Comparative microvessel packing densities
|
|
5
|
Schematic of human breast
|
|
|
6
|
Histological section-breast tissue
|
|
7
|
In situ breast carcinoma
|
|
8
|
Invasive breast cancer
|
|
9
|
Breast cancer cells; vessels
|
|
10
|
Breast cancer slide
|
|
|
11
|
Breast cancer-higher magnification
|
|
12
|
electron micrographs of tumor cells surrounding capillary
|
|
13
|
Diagram-tumor neovascularization
|
|
14
|
Angiogenic vs non-angiogenic tumor cells
|
|
15
|
Angiogenic vs non-angiogenic tumor cells-references
|
|
|
16
|
Dormant Primary Tumors
|
|
17
|
Oncogene Bcl-2 decreases tumor cell apoptosis
|
|
18
|
Increased angiogenesis in prostate carcinomas transfected with Bcl-2
|
|
19
|
Chemotherapy-Mitomycin C
|
|
20
|
Antiangiogenic therapy-TNP-470
|
|
|
21
|
Postive Regulators of Angiogenesis
|
|
22
|
Impact of Oncogenes/Potential Oncogenes on Tumor Angiogenesis
|
|
23
|
Oncogene H-ras
|
|
24
|
Role of oncogenic ras in tumor maintenance
|
|
25
|
Squamous Cell Carcinoma transfected with Thrombospondin ½
|
|
|
26
|
Oncogene/Potential Oncogene Regulation of Angiogenesis
|
|
27
|
Types of Angiogenesis Inhibitors
|
|
28
|
Mechanisms of the Angiogenic Switch
|
|
29
|
Id1 and Id3 required for neurogenesis, angiogenesis
|
|
31
|
Heterogeneity of Angiogenesis
|
|
|
39
|
Horizontal transfer of oncogenes by uptake of apoptotic bodies
|
|
40
|
Antiangiogenic therapy
|
|
44
|
Small facial hemangioma
|
|
45
|
Pre-hemangioma
|
|
46
|
Hemangioma with eye involvement
|
|
|
47
|
Large hemangioma
|
|
48
|
Regression of large hemangioma
|
|
49
|
Key steps demonstrating Interferon-alpha is an angiogenesis inhibitor 1980-89
|
|
50
|
Key steps demonstrating Interferon-alpha is an angiogenesis inhibitor 1992-95
|
|
51
|
Infant with hemangioma of back
|
|
|
52
|
Infant with hemangioma of back-3 months interferon-alpha treatment
|
|
53
|
Infant with regression of hemangioma of back-11 months of treatment
|
|
54
|
Child at 2.5 years
|
|
55
|
Child at 7.5 years
|
|
56
|
Life threatening hemangiomas-10 years experience
|
|
|
57
|
Low grade giant cell tumor of jaw
|
|
58
|
Recurrence of giant cell tumor
|
|
60
|
Giant cell tumor-6 months on interferon-alpha 2A
|
|
61
|
Giant cell tumor-off treatment for 3 years
|
|
62
|
X-ray; off treatment for 1 year
|
|
63
|
X-ray; off treatment for 4 years; bone regrowth
|
|
|
66
|
Infant with angioblastoma of hand
|
|
67
|
Angioblastoma of hand without therapy
|
|
69
|
Angioblastoma of hand-complete regression; interferon 11 months
|
|
70
|
MRI-pelvic tumor
|
|
71
|
MRI-Pelvic tumor 80% regression
|
|
|
72
|
MRI-Pelvic tumor 90% regression
|
|
73
|
Patient post-treatment
|
|
74
|
Case report-Interferon alpha as treatment for hemangioendothelioma
|
|
75
|
Endostatin
|
|
76
|
Endostatin Phase I Clinical Trial Oct 99-Nov 00
|
|
|
77
|
Patient with metastatic pancreatic cancer before treatment
|
|
78
|
Pancreatic cancer; metastases regressing on Endostatin 8 months
|
|
79
|
Angiogenesis Inhibitors-Clinical Trials- March 2001
|
|
80
|
Angiogenesis Inhibitors-Clinical Trials for Eye Diseases-March 2001
|
